Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.